For the first time a diagnostic guide to Alzheimer's disease in the United States released after observation for 27 years of disease that occurs gradually over many years, starting with changes in the brain, and mild memory problems, and eventually become fully dementia.
Released on Tuesday (19 / 4) by the National Institute on Aging and the Alzheimer's Association, guides the emergence of symptoms in the form of mild cognitive impairment or MCI's first-time symptoms more than a decade ago - as a precursor to disease.
In a recent study, known as preclinical Alzheimer's, early stage disease when clumps of protein called amyloid in the brain begin to form healthy people.
This preclinical phase of approximately 10 years before dementia began to appear and begin to do the handling. To these researchers usually bio PET scan, namely the spinal fluid tests and others to predict the emergence of Alzheimer's, a scan is important for researchers and drug companies.
Missing a signal sensitivity of dementia. The stages that mark the disease is different from the guidelines resulting from research conducted by government in 1984, which recognizes only the phase of Alzheimer's dementia when someone loses their memory and ability to care for oneself.
"The biggest difference between then and now is now we consider this process as a continuum that began many years before we make a diagnosis of dementia," said Dr. Guy McKhann of Johns Hopkins University School of Medicine, who worked with the new guidelines, told the media.
Observing the early stages of this disease is important for the next Alzheimer's research, says Dr. Reisa Sperling Brigham and Women's Hospital in Boston, who led the group that wrote the guidelines for preclinical Alzheimer's disease.
"If we are really going to move toward prevention of Alzheimer's disease, we must look at people who do not have symptoms," Sperling said in a telephone interview.
The word 'A' "I think a piece of reality that we are not afraid to dare to say 'A' (Alzheimer's)," said Sperling, who admitted that the diagnosis is frightening.
"I believe the change in cancer 10 or 20 years ago when people become less afraid to utter the word 'C' (cancer). I think it also should be in dealing with Alzheimer's disease," he said.
Sperling said, with the ability to diagnose a person in preclinical Alzheimer's disease, will enable much earlier treatment and prevention efforts. It just like people treating high cholesterol to prevent heart disease.
Sperling and Marilyn Albert of Johns Hopkins University School of Medicine in Baltimore, working under the guidelines in the form of mild cognitive impairment, the researchers said bio, which mentions, these results can not be applied at this time.
"We think, the results can not be used in raktik doctor today. Guideline standard is still not enough. We have not sort out, what is normal and what is not," said Albert.
In January, the Advisory Board of Food and Drug Administration rejected the U.S. agents who conduct the examination of the brain (Eli Lilly) because there are still a lot of data is required before it can be approved to help doctors get rid of the presence of plaques associated with Alzheimer's disease.
Dr. John Ringman, an Alzheimer's researcher at the University of California, Los Angeles, who was not involved in drafting the guidelines, said, defining the initial phase of the disease is a common vocabulary for researchers.
"(That there is today) is really a researcher of language in talking amongst each other," he said.
Ringman said, this will help companies choose the patients in the early stages of disease for clinical trials.
Many researchers believe, to treat Alzheimer's many failures when the disease is already in a further level to be the best way.
0Awesome Comments!